Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our focus is the use of experimental medicine techniques to elucidate the mechanism of action and potential clinical utility of novel therapeutic agents. The core of our work is in rheumatology but as the portfolio expands we are applying these approaches to other therapeutic area.

Experimental medicine is a key technique to elucidate the mechanism of action and potential clinical utility of novel therapeutic agents. This theme has a strong heritage in rheumatology and we maintain strong links with both the Botnar and Kennedy research institutes. Within rheumatology the theme also undertakes later stage (phase 3) studies.

Experimental medicine is not a single trial design, rather an approach that can be applied broadly to evaluate novel therapeutic interventions. Examples of recent and ongoing work include:

  • RIDD Trial. The first targeted therapy trial for early stage Dupuytren's disease. 
  • OPTIMISE trial. Use of novel immunological markers to direct biological therapy in Psoriatic arthritis.
  • Evaluation of novel disease-modifying treatments for osteoarthritis
  • Novel technology to address joint hypoxia

The theme makes use of a dedicated clinical research facility space at the Nuffield Orthopaedic centre and is also closely involved in the creation of a new cross-divisional facility on the Churchill site.